The FDA moved to lock in continuity in two central regulatory divisions, promoting Michael Davis and Karim Mikhail from acting to permanent directors of CDER and CBER, respectively, according to HHS. The appointments follow a period of leadership churn that had rattled parts of the industry and investors. HHS also created a new Deputy Commissioner role focused on technology and artificial intelligence, appointing Jared Seehafer to the position. Industry analysts framed the move as a return to more predictable decision-making, with Davis and Mikhail emphasizing restoration of normal operations and engagement with remaining staff.